中药血管抑制剂人参皂苷Rg3联合紫杉醇治疗胃癌术后肝转移的研究

Rg3 combined with Paclitaxel Chemotherapy on the Patients with Gastric Carcinoma after Surgery and Liver Metastasis

目的:探讨中药血管抑制剂人参皂苷Rg3联合紫杉醇治疗胃癌术后肝转移的临床疗效。方法:39例胃癌术后肝转移患者随机分为治疗组18例,采用中药血管抑制剂人参皂苷Rg3联合紫杉醇为主化疗,对照组21例,采用单纯紫杉醇为主化疗。结果:治疗组总有效率(CR+PR)达66.6%,对照组42.8%,两组比较有显著性差异(P<0.05);两组治疗后血清血管内皮生长因子(VEGF)均有下降,治疗组下降更明显(P<0.01);治疗组在保护免疫功能方面优于化疗组,两组比较有显著性差异(P<0.01);治疗组中位生存期及中位疾病进展时间较对照组延长,两组中位生存期及中位疾病进展时间比较有显著性差异(P<0.05);结论:中药血管抑制剂人参皂苷Rg3联合紫杉醇治疗胃癌术后肝转移能提高总有效率,保护免疫功能,延长中位生存期及中位疾病进展时间。

Objective ：To investigate the clinical benefit of Chinese traditional medicine vas inhibitor Ginsenoside （Rg3） combined with Paclitaxel chemotherapy on the patients with gastric carcinoma after surgery and liver metastasis. Methods ：39 patients with with gastric carcinoma and liver metastasis were divided into 2 groups randomly. Among them, 18 patients received Ginsenoside （Rg3）combined with paclitaxel chemotherapy, the control group ,21 patients were treated with paclitaxel chemotherapy alone. Results ： the overall response rate of the therapy group （ CR and PR） was 66.6% , while the control group was 42.8% , significant difference was observed between the two groups （P 〈 0.05 ） ; the level of VEGF was decreased in both of groups, which of the therapy group was obviously lower than that of the control group（ P 〈0.01 ） ; Protecting immunity ability of the therapy group was significantly higher than that of the chemotherapy group（ P 〈 0.01 ） ; There was significant difference between PFS and TTP of the two groups （ P 〈 0.05 ） ,TIP and PFS of the therapy group were longer than that of the control group. Conclusion ..Ginsenoside（ Rg3 ） combined with Paclitaxel chemotherapy treats the patients with gastric carcinoma after surgery and liver metastasis which may be helpful in enhancing the overall effective rate, protecting the immunity function and lengthening TTP and PFS.